Biotech & Health Tech
Alethio clinches $90M to advance antibody for essential thrombocythemia
About a year after emerging from stealth, University of Oxford spinout Alethio Therapeutics has collected $90 million in a Series A raise to support its lead rare blood cancer program through ...
About a year after emerging from stealth, University of Oxford spinout Alethio Therapeutics has collected $90 million in a Series A raise to support its lead rare blood cancer program through ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗